Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 13, 2020. The document serves as a transaction notification regarding the acquisition of company securities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The transactions were executed on October 9, 2020, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share acquisition transactions.
| Instrument | Transaction Type | Price | Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | Acquisition via Dividend Re-investment | £14.4008 | Various (e.g., 2,223.341 for CEO) | London Stock Exchange |
| American Depositary Shares (USD) | Acquisition via Dividend Re-investment | $37.7256 | Various (e.g., 80.761 for General Counsel) | New York Stock Exchange |
All listed transactions were acquisitions resulting from the re-investment of dividends paid to shareholders on October 8, 2020.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures for insider share acquisitions under a dividend re-investment plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is a statutory notification of specific share transactions.
Investor Verification Checklist
- Verify that the share acquisitions were executed strictly through a dividend re-investment plan and not via open market purchases.
- Confirm the dividend payment date of October 8, 2020, aligns with the company's declared dividend schedule.
- Check the total volume of shares acquired by PDMRs to ensure compliance with internal trading policies and regulatory limits.
- Review the exchange prices (£14.4008 and $37.7256) against the market closing prices on October 9, 2020, to confirm fair execution.